definition for: #advmedprojects

biotechnology, rare disease research, telomeres, anti aging, solidarity

Advanced Medical Projects (AMP) is a biotechnology company with presence in Madrid and Boston. AMP is interested in rare diseases caused by DNA stability, oxidative stress and low telomerase activity, as well as in syndromes caused by accelerated aging where the previous factors prove to be very important. Most of these diseases are pediatric, like dyskeratosis congenita or ataxia telangiectasia, but some are present in adults, like idiopathic pulmonary fibrosis. We follow a “bottom-up” approach to research, studying many different aspects of aging, telomerase function and chromosome stability to understand basic biological and physiological areas. Once we understand basic principles, we look for mechanisms able to act over some particular biochemical and genetic pathway. AMP is the first company to develop a patented family of human peptides as therapeutic product candidates able to increase Telomerase activity in senescent cells, increase DNA repair and also increase cell response against oxidative stress. Most of our drugs are developed as PLGA encapsulated principles to be administered via i.v. once or twice per month. Telomerase is a molecular complex of very difficult biomedical manipulation; its role is to maintain the length of telomeres, which are special DNA sequences located at the end of chromosomes to protect them from degradation.

AMP’s patented GSE24-2 peptides have already demonstrated in vitro potential in several diseases, including cancer, Dyskeratosis Congenita, Werner Syndrome andIdiopathic Pulmonary Fibrosis. GSE24-2 is currently in preclinical studies in animal models and, based on the results generated so far,we hope to reach studies in human patients very soon. Currently, we are also developing new administration platforms for these peptides to determine correct dosage and guarantee safety.

AMP has developed a complete line of cosmetic products using some of its patented molecules. These products are marketed worldwide and 100% of all profits are reinvested to support the research and development of these pediatric drugs.